Educational draft · awaiting clinical reviewUse Rapid for revision, not patient-care decisions. Check current national and local guidance and the BNF or BNFC before acting.
2 min synopsisUK scopeSources checked 12 Sept 2026Clinical review pending
Saved on this device
Synopsis
Distinguish incidental carotid plaque from symptomatic disease, deliver vascular prevention, and reserve intervention for carefully selected higher-risk patients.
New focal neurological symptoms are no longer asymptomatic disease: activate the TIA or stroke pathway immediately and reassess carotid causality.
Do not offer routine population screening for asymptomatic carotid stenosis; low prevalence, false positives and downstream procedural harm undermine net benefit.
Most asymptomatic stenosis receives best medical treatment: smoking cessation, exercise and diet support, blood-pressure and diabetes control, and intensive lipid lowering.
Key red flags
Any new ipsilateral retinal or hemispheric neurological symptom converts the clinical problem to recently symptomatic disease and requires immediate stroke or TIA assessment.
A report of apparent occlusion, near-occlusion or rapidly progressive high-grade stenosis needs expert image review before surveillance or intervention decisions.
New focal deficit after CEA or CAS, severe headache, seizure or neck swelling is a procedural emergency requiring urgent imaging and airway-aware assessment.
New retinal event
Amaurosis fugax or retinal artery occlusion ipsilateral to the lesion makes urgent symptomatic assessment necessary.
New hemispheric event
Contralateral weakness, sensory loss, aphasia or neglect demands immediate TIA or stroke assessment and reclassification.
Investigation priorities
01
Carotid duplex ultrasoundFirst step
Grade stenosis and establish a surveillance baseline
Management branches
ManagementIncidental asymptomatic stenosis
A carotid lesion is found without recent attributable ipsilateral retinal or cerebral symptoms
Verify symptom history, side, duplex quality and NASCET-equivalent severity before calling the disease asymptomatic.
Assess smoking, blood pressure, diabetes, lipids, kidney disease and other vascular beds, then start or optimise prevention.
Key medicines
AtorvastatinFor established cardiovascular disease, offer atorvastatin 80 mg orally once daily unless interactions, adverse-effect risk or preference justify a lower dose; measure lipid response and liver transaminases after 2–3 months.Review pregnancy, active liver disease, interacting medicines, heavy alcohol use and prior muscle toxicity. Use the maximum tolerated intensity when 80 mg is unsuitable; check creatine kinase for unexplained muscle symptoms, transaminases at 12 months, and annual lipids for secondary prevention.
ClopidogrelWhen antiplatelet therapy is selected and aspirin is unsuitable, use the verified product dose of 75 mg orally once daily, with duration reviewed against the patient's vascular indication and bleeding risk.Avoid with active pathological bleeding or severe hepatic impairment. Review occult bleeding, blood counts when symptoms suggest dyscrasia, oral anticoagulants, NSAIDs and other bleeding drugs. Avoid routine omeprazole or esomeprazole because CYP2C19 inhibition may reduce clopidogrel activation; renal experience is limited.
National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 12 Sept 2026; clinical approval remains outstanding.